- Home
- DHR vs SNY Comparison
DHR vs SNY Comparison
Compare DHR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHR
- SNY
- Stock Information
- Founded
- DHR 1969
- SNY 1994
- Country
- DHR United States
- SNY France
- Employees
- DHR N/A
- SNY N/A
- Industry
- DHR Industrial Machinery/Components
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- DHR Industrials
- SNY Health Care
- Exchange
- DHR Nasdaq
- SNY Nasdaq
- Market Cap
- DHR 145.0B
- SNY 116.1B
- IPO Year
- DHR N/A
- SNY N/A
- Fundamental
- Price
- DHR $216.90
- SNY $51.06
- Analyst Decision
- DHR Strong Buy
- SNY Buy
- Analyst Count
- DHR 17
- SNY 4
- Target Price
- DHR $247.75
- SNY $61.50
- AVG Volume (30 Days)
- DHR 4.7M
- SNY 2.9M
- Earning Date
- DHR 10-21-2025
- SNY 10-24-2025
- Dividend Yield
- DHR 0.59%
- SNY 3.13%
- EPS Growth
- DHR N/A
- SNY 105.93
- EPS
- DHR 4.87
- SNY 8.67
- Revenue
- DHR $24,268,000,000.00
- SNY $53,890,648,839.00
- Revenue This Year
- DHR $4.46
- SNY $1.40
- Revenue Next Year
- DHR $5.41
- SNY $6.67
- P/E Ratio
- DHR $44.57
- SNY $5.89
- Revenue Growth
- DHR 2.21
- SNY N/A
- 52 Week Low
- DHR $171.00
- SNY $44.62
- 52 Week High
- DHR $258.23
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- DHR 58.39
- SNY 60.14
- Support Level
- DHR $215.28
- SNY $49.62
- Resistance Level
- DHR $225.05
- SNY $52.20
- Average True Range (ATR)
- DHR 5.43
- SNY 0.72
- MACD
- DHR 0.98
- SNY 0.19
- Stochastic Oscillator
- DHR 44.94
- SNY 73.79
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.